Title: A novel disulfidptosis-related LncRNA prognostic risk model: predicts the prognosis,
tumor microenvironment and drug sensitivity in esophageal squamous cell carcinoma
Version: 1 Date: 01 Nov 2024
Reviewer's report:
This study established a DRG-lncRNA prognostic model that can be used to predict the
prognosis, tumor mutation burden, immune cell infiltration, and drug sensitivity of ECSS
patients. The results of this study provide valuable insights into the understanding of ESCC
and provide valuable assistance for the individualized treatment of ESCC patients. However,
some limitations impair the overall quality. I consider the article publishable with appropriate
revisions.
1. The inclusion and exclusion criteria for cases in TCGA need to be clarified.
2. The authors derived the lncRNAs only by bioinformatic correlation analysis, whether there
is a relationship between them and disulfidptosis needs to be supported by the literature.
3. The authors should appropriately analyze and discuss previous studies on lncRNAs as tumor
biomarkers, especially those based on similar bioinformatics methods (eg.PMID:38681588;
PMID:38371527). This will provide valuable context and enhance the relevance of their
findings.
4. The expression level of LncRNA in vivo is usually low. Did the researchers compare the
basic expression level in the initial screening process? Because if the expression is too low, a
slight increase will show a very high variance change and a low p-value. This extremely low
expression is not of great significance for diagnosis and treatment.
5. There is also a spelling error in the word "sensitivity" in Figures 10.
Title: A novel disulfidptosis-related LncRNA prognostic risk model: predicts the prognosis,
tumor microenvironment and drug sensitivity in esophageal squamous cell carcinoma
Version: 1 Date: 01 Nov 2024
Reviewer's report:
This study established a DRG-lncRNA prognostic model that can be used to predict the
prognosis, tumor mutation burden, immune cell infiltration, and drug sensitivity of ECSS
patients. The results of this study provide valuable insights into the understanding of ESCC
and provide valuable assistance for the individualized treatment of ESCC patients. However,
some limitations impair the overall quality. I consider the article publishable with appropriate
revisions.
1. The inclusion and exclusion criteria for cases in TCGA need to be clarified.
2. The authors derived the lncRNAs only by bioinformatic correlation analysis, whether there
is a relationship between them and disulfidptosis needs to be supported by the literature.
3. The authors should appropriately analyze and discuss previous studies on lncRNAs as tumor
biomarkers, especially those based on similar bioinformatics methods (eg.PMID:38681588;
PMID:38371527). This will provide valuable context and enhance the relevance of their
findings.
4. The expression level of LncRNA in vivo is usually low. Did the researchers compare the
basic expression level in the initial screening process? Because if the expression is too low, a
slight increase will show a very high variance change and a low p-value. This extremely low
expression is not of great significance for diagnosis and treatment.
5. There is also a spelling error in the word "sensitivity" in Figures 10.
Please review this paper.
user
Title: A novel disulfidptosis-related LncRNA prognostic risk model: predicts the prognosis,
tumor microenvironment and drug sensitivity in esophageal squamous cell carcinoma
Version: 1 Date: 01 Nov 2024
Reviewer's report:
This study established a DRG-lncRNA prognostic model that can be used to predict the
prognosis, tumor mutation burden, immune cell infiltration, and drug sensitivity of ECSS
patients. The results of this study provide valuable insights into the understanding of ESCC
and provide valuable assistance for the individualized treatment of ESCC patients. However,
some limitations impair the overall quality. I consider the article publishable with appropriate
revisions.
1. The inclusion and exclusion criteria for cases in TCGA need to be clarified.
2. The authors derived the lncRNAs only by bioinformatic correlation analysis, whether there
is a relationship between them and disulfidptosis needs to be supported by the literature.
3. The authors should appropriately analyze and discuss previous studies on lncRNAs as tumor
biomarkers, especially those based on similar bioinformatics methods (eg.PMID:38681588;
PMID:38371527). This will provide valuable context and enhance the relevance of their
findings.
4. The expression level of LncRNA in vivo is usually low. Did the researchers compare the
basic expression level in the initial screening process? Because if the expression is too low, a
slight increase will show a very high variance change and a low p-value. This extremely low
expression is not of great significance for diagnosis and treatment.
5. There is also a spelling error in the word "sensitivity" in Figures 10.
assistant